Soluble ACE2 has been administered to humans with pulmonary hypertension (Hemnes et al., 2018) and acute respiratory distress syndrome (ARDS) (Khan et al., 2017) at dose ranges of 0.1–0.8 mg/kg and shown to be well tolerated. This evidence concerns the gene ACE2 and acute respiratory distress syndrome.